In order to tailor the site to your needs, please click the button that relates best to you.
So long as you have cookies enabled you will only need to do this once. However, you can change your selection at any time using the dropdown navigation option above the CESPHN logo, top left.
This post is not the latest immunisation update and therefore may contain information or advice that is out of date. Please see our most recent update here.
COVID-19 vaccination update: fighting the Delta variant
Register here for the webinar this Thursday 22 July 7.00pm – 8.30pm
Join Associate Professor Nicholas Wood, Associate Director, Clinical Research and Services, NCIRS Senior Staff Specialist as he discusses COVID-19 vaccines and the conversations GPs need to be having with their patients
practical information to assist GPs in having the AstraZeneca risk/benefit conversation
the link between myocarditis and Pfizer vaccination
impacts different strains of COVID-19 has on the effectiveness of vaccines
the conversation and current data around mixing COVID-19 vaccines
You will also hear practical tips and insights from a local GP on how they run their vaccination clinic, and then from an RN on how they are running their nurse led clinics and drawing up vaccines.
Excess AstraZeneca vaccines
Primary care COVID-19 vaccination sites may choose to transfer AstraZeneca vaccines from one participating vaccination site to another for a range of reasons, including to support unmet demand at another site or to manage an oversupply of stock.
Practices with an oversupply of AstraZeneca vaccine stock on hand are encouraged to contact CESPHN via email at coronavirus@cesphn.com.au to help facilitate transfer to practices to who required additional AstraZeneca vaccine supply.
New pregnancy advice for women who received their first dose of COVID-19 Vaccine AstraZeneca and are now pregnant
New guidance advises that for women who received their first dose of COVID-19 Vaccine AstraZeneca and are now pregnant, can receive their second dose of either COVID-19 Vaccine AstraZeneca or Comirnaty (Pfizer), although Comirnaty is preferred.
Pregnant women should be routinely offered Comirnaty (Pfizer) at any stage of pregnancy. Pregnant women with COVID-19 have an increased risk of severe illness and adverse pregnancy outcomes. It is noted they are not currently picked up by the eligibility checker, however Pfizer vaccination providers are encouraged to facilitate the vaccination of pregnant women, who are not otherwise eligible, if they have capacity. Comirnaty is the preferred COVID-19 vaccine for women who are pregnant due to the amount of safety data available.
Welcome to our new website! As you may have noticed, our website looks different. Central and Eastern Sydney PHN have moved to a new site and although much has remained the same, we have introduced some new functions. These include: Updated navigation When you land on our new website, you…
COVID-19 weekly update – 02 JANUARY 2023 COVID-19 cases in the region Please note: From next week the latest COVID-19 information will be included in the Sydney Health Weekly newsletter, rather than separated at the top. We will still provide COVID-19 related information as well as the dedicated COVID-19 latest…
FIVE QUESTIONS is where we ask members of the community to talk about how they stay HEALTHY. Randwick scientist and grandmother Hilda Stender shared this: What exercise did you do yesterday? I’ve had two knee replacements – one four years ago and the other six months ago. As a result,…
Immunisation weekly update – 1 February 2023 Childhood immunisation overdue reports CESPHN is inviting general practices to sign up to receive a regular report extracted on your behalf from the Australian Immunisation Register (AIR) which is specific to your practice. This report contains all children aged 0-5 living in the CESPHN region…
Australian Digital Health Agency (ADHA) digital health webinars Implementing MyHealth Record Policies in your organisation Thu 9 Feb 23, 12.30-1.00 pm – learn how to implement and maintain a My Health Record Security and Access policy in your organisation. Understand the importance of the Responsible Officer (RO) and Organisational Maintenance…
UNSW research – Palliative care and intellectual disability A research team led by Professor Julian Trollor at the Department of Developmental Disability Neuropsychiatry, UNSW Sydney, aims to design, implement, and evaluate a new palliative care service for people with intellectual disability. This is important because people with intellectual disability often…
GP support needed: Shared e-Care plan study for follow-up of colorectal and breast cancers This research evaluates shared care using a new interactive e-care plan being implemented through cancer services in Prince of Wales and St George public and private hospitals. Through the e-care plan GPs, cancer specialists and patients…